Galapagos Seeks Partner For Recently Acquired Low-Dose Estrogen Product
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm continues its acquisition program with the purchase of ProStrakan’s bone disease unit for a maximum value of $60 million.